BRPI0716583A2 - ligandos fluorados para marcar recptores de benzodiazepina perifÉricos - Google Patents

ligandos fluorados para marcar recptores de benzodiazepina perifÉricos

Info

Publication number
BRPI0716583A2
BRPI0716583A2 BRPI0716583-8A2A BRPI0716583A BRPI0716583A2 BR PI0716583 A2 BRPI0716583 A2 BR PI0716583A2 BR PI0716583 A BRPI0716583 A BR PI0716583A BR PI0716583 A2 BRPI0716583 A2 BR PI0716583A2
Authority
BR
Brazil
Prior art keywords
benzodiazepine receptors
peripheral benzodiazepine
fluorinated ligands
label peripheral
label
Prior art date
Application number
BRPI0716583-8A2A
Other languages
English (en)
Inventor
Andrew Katsifis
Christopher John Reginald Fookes
Tien Quoc Pham
Ivan Damir Greguric
Soares Mattner Maria Filomena Pereira
Original Assignee
Australian Nuclear Science Tec
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2006904617A external-priority patent/AU2006904617A0/en
Application filed by Australian Nuclear Science Tec filed Critical Australian Nuclear Science Tec
Publication of BRPI0716583A2 publication Critical patent/BRPI0716583A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0716583-8A2A 2006-08-24 2007-08-24 ligandos fluorados para marcar recptores de benzodiazepina perifÉricos BRPI0716583A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2006904617A AU2006904617A0 (en) 2006-08-24 Fluorinated ligands for targeting peripheral benzodiazepine receptors
AU2006907288A AU2006907288A0 (en) 2006-12-22 Radiolabelled and non radiolabelled flurinated ligands for targeting peripheral benzodiazepine receptors
PCT/AU2007/001216 WO2008022396A1 (en) 2006-08-24 2007-08-24 Fluorinated ligands for targeting peripheral benzodiazepine receptors

Publications (1)

Publication Number Publication Date
BRPI0716583A2 true BRPI0716583A2 (pt) 2013-10-01

Family

ID=39106394

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0716583-8A2A BRPI0716583A2 (pt) 2006-08-24 2007-08-24 ligandos fluorados para marcar recptores de benzodiazepina perifÉricos

Country Status (12)

Country Link
US (1) US20100209345A1 (pt)
EP (2) EP2054060B1 (pt)
JP (1) JP2010501491A (pt)
KR (1) KR20090063220A (pt)
CN (1) CN101528226B (pt)
AU (1) AU2007288124B2 (pt)
BR (1) BRPI0716583A2 (pt)
CA (1) CA2660169A1 (pt)
IL (1) IL197219A0 (pt)
MX (1) MX2009002060A (pt)
RU (1) RU2468014C2 (pt)
WO (1) WO2008022396A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2710016A1 (en) * 2007-12-21 2009-07-02 The University Of Sydney Translocator protein ligands
AU2009249186B2 (en) * 2008-05-19 2014-05-22 Sunovion Pharmaceuticals Inc. Imidazo [1, 2-a] pyridine compounds as GABA-A receptor modulators
US20110142757A1 (en) * 2008-08-19 2011-06-16 The University Of Sydney Novel compounds and their uses in diagnosis
WO2010032195A1 (en) * 2008-09-16 2010-03-25 Csir Imidazopyridines and imidazopyrimidines as hiv-i reverse transcriptase inhibitors
EP2181717A1 (en) * 2008-10-28 2010-05-05 Sanofi-Aventis Use of 7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-B]indole-1-acetamide as a biomarker of peripheral benzodiazepine receptor levels
CN102292461A (zh) * 2008-12-22 2011-12-21 拜耳先灵医药股份有限公司 使用交换树脂合成放射性核素标记的化合物的方法
CN102834379B (zh) * 2010-03-26 2014-12-24 通用电气健康护理有限公司 作为pbr配体的三环吲哚衍生物
CN102295642B (zh) * 2010-06-25 2016-04-06 中国人民解放军军事医学科学院毒物药物研究所 2-芳基咪唑并[1,2-a]吡啶-3-乙酰胺衍生物、其制备方法及用途
WO2012080834A1 (en) 2010-12-17 2012-06-21 Rhodes Technologies Low-temperature synthesis of methylphenidate hydrochloride
TWI617559B (zh) * 2010-12-22 2018-03-11 江蘇恆瑞醫藥股份有限公司 ２－芳基咪唑并［１，２－ｂ］嗒．２－苯基咪唑并［１，２－ａ］吡啶，和２－苯基咪唑并［１，２－ａ］吡衍生物
WO2012143796A2 (en) * 2011-04-21 2012-10-26 Institut Pasteur Korea Anti-inflammation compounds
WO2012168697A1 (en) 2011-06-06 2012-12-13 Imperial Innovations Limited Methods to predict binding affinity of tspo imaging agents to tspo
US9458161B1 (en) 2011-11-03 2016-10-04 Vanderblit University TSPO ligands for cancer imaging and treatment
US9498546B2 (en) 2012-03-14 2016-11-22 The Johns Hopkins University Synthesis and application of novel imaging agents conjugated to DPA 713 analogs for imaging inflammation
SG11201701580XA (en) 2014-08-29 2017-03-30 Chdi Foundation Inc Probes for imaging huntingtin protein
HRP20211778T1 (hr) 2014-08-29 2022-03-18 Chdi Foundation, Inc. Kontrastna sredstva za slikovnu dijagnostiku huntingtin proteina
US12282014B2 (en) 2015-11-19 2025-04-22 Dana-Farber Cancer Institute, Inc. Methods of identifying compounds that interfere with ERG-driven misguidance of BAF complexes in TMPRSS2-ERG driven prostate cancers
EP3468545B1 (en) 2016-06-08 2026-08-05 President and Fellows of Harvard College Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, rett syndrome, and fragile x syndrome
EP3746124A4 (en) 2018-01-30 2021-10-27 Foghorn Therapeutics Inc. COMPOUNDS AND THEIR USES
WO2019226808A1 (en) 2018-05-22 2019-11-28 President And Fellows Of Harvard College Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
EP3801512A4 (en) * 2018-05-29 2022-01-19 President and Fellows of Harvard College COMPOSITIONS AND METHODS TO REDUCE TACTILE DYSFUNCTION, ANXIETY AND SOCIAL DISABILITIES
US12473334B2 (en) 2018-10-17 2025-11-18 Dana-Farber Cancer Institute, Inc. SWI/SNF family chromatin remodeling complexes and uses thereof
CN109734720A (zh) * 2019-01-28 2019-05-10 中国人民解放军东部战区总医院 18f标记dpa-714类衍生物及其制备方法和应用
US12509453B2 (en) 2019-01-29 2025-12-30 Foghorn Therapeutics Inc. BRM/BRG1 inhibitors and uses thereof
US12384776B2 (en) 2019-01-29 2025-08-12 Foghorn Therapeutics Inc. Compounds and uses thereof
US12077512B2 (en) 2019-03-25 2024-09-03 President And Fellows Of Harvard College Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
WO2021155262A1 (en) 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2021155264A1 (en) * 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
US12383555B2 (en) 2020-05-20 2025-08-12 Foghorn Therapeutics Inc. Methods of treating cancers
US12606553B2 (en) 2021-03-09 2026-04-21 Foghorn Therapeutics Inc. Crystalline forms, compositions containing same, and methods of their use
CN117534671B (zh) * 2023-11-10 2026-05-12 宁夏师范学院 二氯二茂钛催化合成咪唑并[1,2-α]吡啶衍生物的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2492382A1 (fr) * 1980-10-22 1982-04-23 Synthelabo Derives d'imidazo (1,2-a) pyridine, leur preparation et leur application en therapeutique
JPH09176165A (ja) * 1995-12-25 1997-07-08 Nippon Nohyaku Co Ltd イミダゾ［１，２−ａ］ピリジン誘導体、その製法およびその用途
AUPP278498A0 (en) * 1998-04-03 1998-04-30 Australian Nuclear Science & Technology Organisation Peripheral benzodiazepine receptor binding agents
JP4025468B2 (ja) * 1999-07-29 2007-12-19 三井化学株式会社 有機電界発光素子
US20020107262A1 (en) * 2000-12-08 2002-08-08 3M Innovative Properties Company Substituted imidazopyridines
MX2007005611A (es) * 2004-11-11 2007-07-11 Ferrer Int Compuestos de imidazo[1,2-a]piridina, composiciones, usos y metodos relacionados.
US20070031328A1 (en) * 2005-06-24 2007-02-08 Kung Hank F Radiolabeled-pegylation of ligands for use as imaging agents
KR20090028714A (ko) * 2006-05-19 2009-03-19 더 유니버시티 오브 시드니 전좌 단백질(18 ＫＤＡ)의 리간드로서의 2-아릴피라졸로[Ｌ,5-α]피리미딘-3-일 아세트아미드 유도체

Also Published As

Publication number Publication date
EP2054060A4 (en) 2010-10-20
EP2752415A1 (en) 2014-07-09
AU2007288124A1 (en) 2008-02-28
JP2010501491A (ja) 2010-01-21
KR20090063220A (ko) 2009-06-17
RU2009110480A (ru) 2010-09-27
EP2054060A1 (en) 2009-05-06
HK1126418A1 (en) 2009-09-04
MX2009002060A (es) 2009-03-09
CA2660169A1 (en) 2008-02-28
RU2468014C2 (ru) 2012-11-27
EP2054060B1 (en) 2014-04-02
CN101528226B (zh) 2012-01-11
CN101528226A (zh) 2009-09-09
US20100209345A1 (en) 2010-08-19
WO2008022396A1 (en) 2008-02-28
EP2752415B1 (en) 2017-10-11
IL197219A0 (en) 2009-12-24
AU2007288124B2 (en) 2013-04-04
EP2752415B8 (en) 2017-11-15

Similar Documents

Publication Publication Date Title
EP2036018A4 (en) MIDDLEWARE ADVERTISING
DK2064228T3 (da) Syntetiske peptidamider
DE602007003427D1 (de) Motorrad
DE602006011058D1 (de) Kontinuierliches backup
ITRM20070190A1 (it) Motorcycle
DE602007004016D1 (de) Fahrradkurbel
BRPI0717070A2 (pt) compostos de tiofeno pirazolopirimidina
DE602007003411D1 (de) Motorrad
DE112008003198A5 (de) Schmierstoffgeber
DE602007001442D1 (de) Motorrad
EP2344568A4 (en) ACETYLENPOLYAMID
DE602007000714D1 (de) Motorrad
DE602007002436D1 (de) Motorrad
DE602007011150D1 (de) Motorrad
ATE467618T1 (de) Chinolinylmethylverbindungen
EP2059496A4 (en) acetylene
DE602007001380D1 (de) Motorrad
FI20060763A0 (fi) Öljypuomi
EP2014216A4 (en) APPLICATOR
DE602007011530D1 (de) Motorrad
DE602007003264D1 (de) Scooterähnliches Motorrad
DE602008001051D1 (de) Motorrad
UA14435S (uk) Етикетка для масла
UA12644S (uk) Мило
UA12664S (uk) Мило

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2320 DE 23-06-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.